Madison Area Lyme Support Group

Introduction This observational study looked at 255 COVID19 patients who required invasive mechanical ventilation (IMV) during the first two months of the US pandemic. Through comprehensive, longitudinal evaluation and new consideration of all the data, we were able to better describe and understand factors affecting outcome after intubation.

Methods All vital signs, laboratory values, and medication administrations (time, date, dose, and route) were collected and organized. Further, each patient’s prior medical records, including PBM data and available ECG, were reviewed by a physician. These data were incorporated into time-series database for statistical analysis.

Results By discharge or Day 90, 78.2% of the cohort expired. The most common pre-existing conditions were:

• hypertension, (63.5%)
• diabetes (59.2%)
• obesity (50.4%)

Age correlated with death. Comorbidities and clinical status on presentation were not predictive of outcome. Admission markers of inflammation were universally elevated (>96%). The cohort’s weight range was nearly 7-fold.

Causal modeling establishes that weight-adjusted HCQ and AZM therapy improves survival by over 100%.

QTc prolongation did not correlate with cumulative HCQ dose or HCQ serum levels.

Discussion This detailed approach gives us better understanding of risk factors, prognostic indicators, and outcomes of Covid patients needing IMV. Few variables were related to outcome. By considering more factors and using new methods, we found that when increased doses of co-administered HCQ and AZM were associated with >100% increase in survival. Comparison of absolute with weight-adjusted cumulative doses proves administration ≥80 mg/kg of HCQ with > 1 gm AZM increases survival in IMV-requiring Covid patients by over 100%. According to our data, HCQ is not associated with prolongation.

Studies, which reported QTc prolongation secondary to HCQ, need to be re-evaluated more stringently and with controls.

The weight ranges of Covid patient cohorts are substantially greater than those of most antibiotic RCTs. Future clinical trials need to consider the weight variance of hospitalized Covid patients and need to study therapeutics more thoughtfully.

___________________

**Comment**

We were told from the beginning by doctors treating COVID patients that HCQ, azithromycin, and zinc works.  Unfortunately, this beneficial treatment, along with Ivermectin and others was smeared and censored by public health ‘authorities’ and main stream media (along with the doctors advocating them).  We were also told all of a sudden HCQ is dangerous (QTc prolongation) despite decades of safe usage.  Then the ‘powers that be’ even published a faulty study on it that had to be retracted.  A doctor took the time to really sift through the burgeoning, government funded HCQ studies and discovered the dosages given were enough to kill a horse.

The false narrative that there aren’t any effective treatments for COVID continues to this day so everyone will remain fearful and get the experimental, fast-tracked COVID jab despite thousands of reports of death and severe adverse reactions – which continue to mount.  Vaccine experts also continue to warn about the dangerous spike protein in the injections that circulate in the body causing deadly reactions. Virologists are warning that mass vaccination is causing mutant or variant strains to develop which will be more severe and more resistant to vaccines.

We’ve been warned about antibody dependent enhancement (ADE) or pathogenic priming which is currently being seen in countries undertaking mass vaccination:

Montagnier states,

“You see it in each country, it’s the same: the curve of vaccination is followed by the curve of deaths.  I’m following this closely and I a doing experiments at the Institute with patients who became sick with Corona after being vaccinated.”